Latest Updates of Companies in the Biotherapeutics Market
| Company | Headquarters | Latest Update |
| Pfizer Inc. | United States | Pfizer's ELREXFIO significantly enhances progression-free survival for double-class-exposed patients with relapsed or refractory multiple myeloma. |
| Sanofi | France | Sanofi's goal is to fund cutting-edge translational research that contributes to the early-stage pipeline and ultimately benefits patients. |
| Novartis AG | Switzerland | In March 2026, Novartis announced that it had agreed to acquire Excellergy, Inc., a private biotech organisation developing next-generation anti-IgE therapies for IgE-driven diseases. |
| AstraZeneca | United States | In March 2026, AstraZeneca will build a dedicated cell therapy commercial manufacturing and supply base in the Lingang New Area of the Shanghai Free Trade Zone for the commercial manufacturing and supply of autologous CAR-T cell therapies. |
| Biogen | Switzerland | Specialised in neurologic and neurodegenerative disease therapies. |
Supply Chain Analysis
R&D:
- R&D processes in biotherapeutics include a challenging, multi-stage, and highly regulated cycle with the goal of creating medicines from biological sources, like proteins, cells, tissues, and genes.
- Key Players: Johnson & Johnson and Novo Nordisk A/S
Manufacturing Processes:
- Manufacturing processes for biotherapeutics include challenging, multi-stage procedures to produce therapeutic proteins, antibodies, and cellular therapies using living cells.
- Key Players: Eli Lilly and Company and F. Hoffmann-La Roche Ltd.
Patient Services:
- Patient services in biotherapeutics, which involve biologics such as monoclonal antibodies, vaccines, and gene therapies, significantly focus on managing the complexities of these progressive treatments.
- Key Players: AbbVie Inc. and Amgen Inc.
Recent Developments in the Biotherapeutics Market
- In May 2026, Viridian Therapeutics, Inc., a biotechnology company focused on discovering, advancing, and commercialising potentially best-in-class medicines for autoimmune and rare diseases, announced positive topline data from the REVEAL‑2 phase 3 clinical trial of elegrobart in patients with chronic thyroid eye disease (TED).
- In May 2026, Esperion Therapeutics, a commercial-stage biopharmaceutical organisation dedicated to developing and delivering innovative cardiometabolic and rare/orphan disease therapies, and ARCHIMED, an important spending firm focused exclusively on medical care industries, announced that they have entered into a definitive agreement under which funds managed by ARCHIMED acquire Esperion in a transaction valued at up to approximately $1.1 billion
- In May 2026, UCB, a worldwide biopharmaceutical organisation, announced the signing of a definitive agreement in which it would acquire Candid Therapeutics, a privately held clinical-stage biotechnology company redefining the treatment of autoimmune and inflammatory diseases via novel T-cell engagers (TCEs).
Market Growth
The global biotherapeutics market size was estimated at USD 485.72 billion in 2025 and is predicted to increase from USD 533.51 billion in 2026 to approximately USD 1241.63 billion by 2035, expanding at a CAGR of 9.84% from 2026 to 2035.
Keypoints
- Company Overview
- Locations Subsidiaries/Geographic reach
- Key Executives
- Company Financials
- Patents registered
- SWOT Analysis
- Applications Catered
- Strategic collaborations
- Recent Developments
- Competitive Benchmarking